Hennion & Walsh Asset Management Inc. Increases Stock Position in Viridian Therapeutics, Inc. $VRDN

Hennion & Walsh Asset Management Inc. grew its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 19.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 209,092 shares of the company’s stock after purchasing an additional 34,198 shares during the quarter. Hennion & Walsh Asset Management Inc. owned approximately 0.20% of Viridian Therapeutics worth $3,841,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of VRDN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Viridian Therapeutics by 1.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after buying an additional 876 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Viridian Therapeutics by 33.8% during the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after buying an additional 310,998 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Viridian Therapeutics by 12.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock worth $1,760,000 after buying an additional 14,788 shares in the last quarter. Envestnet Asset Management Inc. acquired a new position in shares of Viridian Therapeutics in the second quarter worth $187,000. Finally, Creative Planning acquired a new position in shares of Viridian Therapeutics in the second quarter worth $179,000.

Analysts Set New Price Targets

A number of research firms recently commented on VRDN. Stifel Nicolaus set a $39.00 price objective on Viridian Therapeutics in a research note on Wednesday, May 13th. Evercore set a $26.00 target price on shares of Viridian Therapeutics in a research note on Friday, May 15th. Wall Street Zen lowered shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. The Goldman Sachs Group reaffirmed a “buy” rating and set a $39.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, June 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $32.00 price target on shares of Viridian Therapeutics in a report on Monday, June 29th. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.93.

Viridian Therapeutics Trading Down 2.2%

NASDAQ VRDN opened at $23.06 on Tuesday. The company has a market cap of $2.61 billion, a P/E ratio of -6.84 and a beta of 0.91. Viridian Therapeutics, Inc. has a 12 month low of $13.18 and a 12 month high of $34.29. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15. The company has a 50-day moving average of $18.51 and a 200-day moving average of $21.52.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Thursday, August 6th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.02). Viridian Therapeutics had a negative return on equity of 76.65% and a negative net margin of 505.86%.The company had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.06 million. As a group, equities analysts predict that Viridian Therapeutics, Inc. will post -4.02 earnings per share for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.